Pfizer To Pay $486M To Settle Celebrex, Bextra Securities MDL
Pfizer Inc. will pay $486 million to settle long-running multidistrict litigation accusing it of misleading investors about the alleged risks of its pain treatments Celebrex and Bextra, according to an earnings...To view the full article, register now.
Already a subscriber? Click here to view full article